Sustained Gains for DMD Boys Evident in SRP-9001 Trials: Sarepta

Sustained Gains for DMD Boys Evident in SRP-9001 Trials: Sarepta

309229

Sustained Gains for DMD Boys Evident in SRP-9001 Trials: Sarepta

New data across clinical trials of SRP-9001 show the investigative gene therapy induces sustained functional improvements in people with Duchenne muscular dystrophy (DMD), and does so with good tolerability, Sarepta Therapeutics, its developer, announced. The company, in presenting these data, also offered more details about the recently launched and pivotal Phase 3 EMBARK trial. “With 77 patients treated to date, the multi-study development program for SRP-9001 represents the most comprehensive and long-term dataset for a Duchenne muscular dystrophy gene…

You must be logged in to read/download the full post.